GNLX

GeneluxA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$6.00

Analysis reference price unavailable

Analysis 2026-10-22 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$2.30

Analysis reference price unavailable

Analysis 2026-10-22 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.70

Analysis reference price unavailable

Analysis 2026-10-22 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-22

AI commentary

Company-reported clinical progress supports a tentative positive bias, but the September SCLC report is a low-signal single-patient observation. No attributable recent price reaction, analyst revisions, sufficient social coverage, options skew, short-interest reading or employee score was supplied. Zero-valued sentiment fields mean unavailable, not neutral. Coverage and peer comparability remain limited.

RankAlpha Sentiment Codex - 2026-10-22

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventPhase 3 OnPrime ovarian-cancer topline resultsHigh impact

Genelux expects topline results in the second half of 2026 from its randomized Phase 3 Olvi-Vec trial in platinum-resistant or refractory ovarian cancer. The result is the principal value-defining event; efficacy and safety remain unproven. [#PR-EARNINGS-2026-08-13] https://investors.genelux.com/news-releases/news-release-details/genelux-corporation-reports-second-quarter-financial-results-and

2026-12-31catalystSystemic Olvi-Vec lung-cancer dose-finding updatesHigh impact

The company expects further 2026 updates from its SCLC and NSCLC dose-escalation studies. Its September SCLC case report concerns one patient and cannot establish cohort-level efficacy. [#PR-EARNINGS-2026-08-13] [#PR-2026-09-09] https://investors.genelux.com/news-releases/news-release-details/genelux-announces-publication-deep-and-durable-response-platinum

2027-03-31catalystCash-runway and financing decisionHigh impact

Genelux reported $18.7 million of cash, cash equivalents, marketable securities and restricted cash at June 30, 2026, and expected funding into the first quarter of 2027. Raising capital could dilute shareholders, particularly after an unfavorable trial result. [#PR-EARNINGS-2026-08-13] https://investors.genelux.com/news-releases/news-release-details/genelux-corporation-reports-second-quarter-financial-results-and

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-22 • Updated nightlySource: Internal modelMethodology